ParaplegiaKER-EXHOMENCT07828912
Personal Exoskeleton or Manual Wheelchair: a Comparison of Performance and Satisfaction in Activities of Daily Living Among People With Spinal Cord Injuries, Using the SCED Methodology.
A study testing Carrying out tasks using the EVE exoskeleton and a manual wheelchair. in people with Paraplegia and Spinal Cord Injury, run by Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape at 1 site in France.
Trial summary
Spinal cord injuries resulting in paraplegia affect patients' mobility and, consequently, their ability to participate in activities of daily living. In France, according to available sources, the number of people with a symptomatic spinal cord injury is estimated to be between 97,000 and 132,000, with an average age… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Paraplegia, Spinal Cord Injury
- What is being tested?
- Carrying out tasks using the EVE exoskeleton and a manual wheelchair.
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical presentation of paraplegia at a level between T5 and L5 inclusive, AIS A to C inclusive
- Secondary to a spinal cord injury (traumatic or non-traumatic) occurring more than 6 months ago, clinically and functionally stable
- Using a manual wheelchair for indoor and outdoor mobility
- Able to tolerate 45 minutes of standing per day
- Anthropometric compatibility with the device (weight, height, lower limb measurements, joint ranges of motion);
- Whether or not they have previous experience of using a PPE;
- Participants who have signed the written consent form to take part in the study following full and informed consent
- Participants covered by a social security scheme (beneficiary or eligible dependant) other than the AME.
Who cannot join
- Osteoporosis with a T-score < -2.5 at the femoral neck, as shown by a bone densitometry scan carried out within the last 12 months.
- History of osteoporotic fracture(s)
- Condition or treatment causing secondary osteoporosis (known thyroid disorder, known hypogonadism, known chronic gastrointestinal disease (ulcerative colitis and Crohn's disease), corticosteroid therapy, use of bisphosphonates for more than three months, early menopause (before the age of 45), abnormal calcium metabolism test results)
- Progressive intercurrent conditions: pressure ulcers, infection, venous thrombosis
- Cardiovascular or pulmonary conditions contraindicating exercise (e.g. heart failure or coronary artery disease within the last 6 months)
- Untreated or uncontrolled hypertension (SBP > 140 mmHg; DBP > 90 mmHg);
Show all 24Show fewer
- Unresolved orthostatic hypotension (SBP < 90 mmHg; DBP < 60 mmHg) or deemed contraindicated by the investigator;
- Unconsolidated or unstable bone lesions of the spine, limbs or pelvis
- Known syringomyelia, as determined by medical assessment
- Progressive osteoma, as determined by medical assessment
- Severe spasticity of the adductor muscles, hamstrings, quadriceps and triceps surae (greater than 3 on the modified Ashworth scale)
- Decompensated psychiatric or cognitive disorders that may interfere with the proper use of the device
- Stoma
- Wearing of an active implantable device An uncorrectable leg-length discrepancy of more than 2 cm when using additional corrective aids
- Uncontrolled autonomic dysreflexia
- Skin lesions at points of contact with the PPE (e.g. bruising, skin abrasions, etc.)
- Need to use a respiratory support device whilst using Eve
- Inability to operate the device effectively using a manual control interface, due to a functional and/or cognitive impairment, based on the ability to move the joystick in all directions, press and identify the buttons on the manual control interface.
- Incorrect positioning of the participant in the device (excessive pressure on the support point).
- Participant deprived of liberty (by court order or administrative decision)
- Participant of legal age subject to a legal protection order or unable to give informed consent
- Participation in another ongoing clinical trial
- Pregnant or breastfeeding women, or women of childbearing age not using contraception
- Lack of proficiency in spoken and written French
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Marie-Caroline Delebecque, project manager contact
France1 site
Centre de Kerpape
Ploemeur, 56270
Charline Longuet, clinical research assistant, 02.97.82.60.67 ext. +33, charline.longuet@vyv3.fr
Marie-Caroline Delebecque, project manager, charline.longuet@vyv3.fr
About this study
Spinal cord injuries resulting in paraplegia affect patients' mobility and, consequently, their ability to participate in activities of daily living. In France, according to available sources, the number of people with a symptomatic spinal cord injury is estimated to be between 97,000 and 132,000, with an average age of 55. The incidence is estimated at 1,300 new cases per year.
Following initial treatment, patients' aim is to resume their daily activities. Engaging in these activities is associated with a better quality of life and is recognised as having a positive effect on health. Limitations in their ability to move around directly affect their participation in activities of daily living and, consequently, their quality of life.
Read more
To this end, mobility can be supported by a manual wheelchair (MW) or an electric wheelchair (EW); however, these aids do not enable patients to regain the ability to stand, which remains one of the main goals for people with spinal cord injuries.
Robotic exoskeletons can assist with standing and locomotion. To date, robotic exoskeletons have been used in rehabilitation centres. During the rehabilitation phase, these devices have proven to be usable and safe for a wide range of patients with spinal cord injuries. Motorised exoskeletons thus enable patients to perform tasks such as walking, standing upright, rotating, and carrying out dynamic balance exercises.
In the longer term, personal exoskeletons, used at home, could facilitate the performance of productive, domestic, social or recreational activities, such as those carried out on a daily basis by every individual.
Personal powered exoskeletons (PPEs) also appear to generate physiological and psychosocial benefits. Studies describe potential improvements in cardiovascular health, bladder and sphincter function, and a reduced risk of osteoporosis. After a few weeks of training with a motorised exoskeleton, patients report improvements in social functioning, mental health and sub-domains of general health perception on the SF36 Walk Wheel.
It should be noted that the ability to interact socially whilst standing is an important aspect of quality of life for patients with spinal cord injuries. Patients describe the pleasure of eye contact, of being able to walk with assistance, and an improvement in mood. The PPE would complement the wheelchair by enabling ambulation and participation in activities whilst standing.
Preserving upper limb function is a prerequisite for the widespread use of walking exoskeletons in everyday life. A self-supporting PPE, such as the EVE® device, which does not require the use of crutches, aims to enable users to stand up and walk whilst retaining the use of their upper limbs. This active balance control is a crucial function for achieving many functional skills in a domestic environment. One of the technological advantages of the self-balancing exoskeleton lies in the use of dynamics to eliminate the need for crutches, whilst ensuring walking safety.
The next step towards the development of personal exoskeletons for people with spinal cord injuries is to investigate the performance of activities of daily living whilst wearing an exoskeleton. To our knowledge, no such study has been carried out, and our work addresses a gap in the scientific literature by analysing the impact of using a self-propelled PPE on satisfaction and performance when carrying out activities of daily living.
The investigators hypothesise that the personal exoskeleton leads to greater satisfaction when carrying out the four tasks of daily living, compared with that achieved using a manual wheelchair.
In this context, the KER-EXHOME clinical trial, proposed by Dr Stéphanie LEPLAIDEUR (coordinator of this study), and led by the Kerpape Centre (sponsor), aims to compare, in participants with paraplegia, satisfaction and performance when carrying out activities of daily living and physical activities, using the EVE® device compared with a manual wheelchair.
Read the detailed description
The KER-EXHOME study is a single-case experimental design (SCED) with multiple baseline conditions. This methodology enables the analysis of data from a limited number of subjects and is based on three principles: each subject serves as their own control; frequent, repeated measurement of each subject's performance throughout the study phase; and the sequential, randomised introduction of the intervention during the study, which ensures the necessary statistical power.
- Conditions
- Paraplegia, Spinal Cord Injury
- Being tested
- Carrying out tasks using the EVE exoskeleton and a manual wheelchair.
- Keywords
- manual wheelchair, exoskeleton, personal powered exoskeleton, everyday tasks, satisfaction, performance
- Medical subject headings
- Paraplegia, Spinal Cord Injuries, Personal Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Carrying out tasks using the EVE exoskeleton and a manual wheelchair.Device
Each day (Monday to Friday), participants will have a 3½-hour session. During each session, tasks will need to be carried out using the EVE® exoskeleton and the manual wheelchair. The tasks have been grouped in pairs so that two tasks are carried out in succession. These task groups have been assigned a number, as follows: 1- Archery and retrieving a parcel 2- Making coffee and brushing teeth During a session, the participant will carry out one task group using both devices: the EVE® exoskeleton and the manual wheelchair. These devices have been assigned a letter, as follows: A- EVE® exoskeleton B- Manual wheelchair A random allocation will be used to determine the order of the parameters (B-wheelchair or A-EVE® exoskeleton), the time of day (morning or afternoon), and the task group to be performed in each session for each participant (1 or 2).
| Study group | Role | What they receive |
|---|---|---|
| Carrying out tasks using the EVE exoskeleton and a manual wheelchair. | Experimental | Training Phase, Week 1
The training phase for operating the EVE® exoskeleton covers the following functions (designed to ensure that the participant is trained in the use of the EVE® exoskeleton):
* Standing up;
* Testing in free mode;
* Walking;
* Turning round;
* Half-squat;
* Using precision mode;
* Sitting down;
* Carrying out emergency extraction training;
* Archery training, if the participant has no prior experience. Participants will undergo training over 5 sessions, each lasting at least 60 minutes, spread over one week. A minimum of 5 hours' training is required to ensure safety.
Intervention phase, weeks 2 to 4 During this phase, participants will have a 3½-hour session every day (Monday to Friday). During each session, tasks will need to be carried out using the EVE® exoskeleton and the manual wheelchair. Receives: Device: Carrying out tasks using the EVE exoskeleton and a manual wheelchair. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare satisfaction and performance when carrying out four activities of daily living using the EVE® exoskeleton, versus those carried out using a manual wheelchair, using the Canadian Occupational Performance Measure (COPM)
The Canadian Occupational Performance Measure (COPM) will be used to compare perceived satisfaction and performance when carrying out identified activities of daily living using either the EVE® exoskeleton or a manual wheelchair. Using the COPM, satisfaction and performance are assessed on a scale of 1 to 10 (1 = very poor performance and satisfaction, 10 = full performance and satisfaction). MCRO scores show a significant improvement between the start and end of treatment; in the SCI validation study, the average improvement reported is approximately 4.25 points (Performance) and 2.96 points (Satisfaction) between two measurement points.
The MCRO will be carried out at the end of each session using one of the devices (wheelchair or exoskeleton). Two assessments must be carried out per half-day.
Measured: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Secondary outcomes (6)
Compare user-assessed performance with clinician-assessed performance, using the Performance Quality Rating Scale (PQRS)
Measurement of task performance as reported by the clinician (occupational therapist and physiotherapist). Clinicians assess overall performance on a scale of 1 to 10 (1 being a failure and 10 being optimal performance) after each session.
The PQRS scale will be completed immediately after each task is performed for each of the two devices (wheelchair and PPE). Thus, four scores must be recorded per half-day.
Measured: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Time taken to complete each task (in seconds).
The time will be recorded upon completion of each task, whether carried out in a wheelchair or using the PPE.
Thus, four times will need to be recorded per half-day.
Measured: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
To evaluate the user's perception of the ease of use of the EVE® exoskeleton, using the System Usability Scale (SUS)
The System Usability Scale (SUS) is a standardised questionnaire for measuring the usability of interactive systems, comprising ten items formulated as affirmative statements. For each statement, the user is asked to indicate their agreement or disagreement using a 5-point Likert scale (1 = Strongly disagree; 5 = Strongly agree). If the user is unsure how to respond to an item, they are asked to answer it anyway by ticking the centre of the scale (score 3).
Its aim is to measure users' perceptions of a product or service based on their experiences.
The SUS will be assessed at the end of each week. Three SUS ratings will be carried out during the intervention phase.
Measured: Intervention phase (Week 2 to 4) : Day 12, Day 19, Day 26
To assess the psychosocial impact of the EVE® exoskeleton using the French-Canadian version of the F-PIADS scale, which measures the psychosocial impact of an assistive device.
This is a 26-item questionnaire that measures the impact on quality of life (psychosocial effects) of using a functional aid from the perspective of the person with a disability, by assessing three concepts: Competence (12 items), Adaptability (6 items) and Self-esteem (8 items).
When completing the questionnaire, the respondent rates each item on a 7-point Likert scale ranging from -3 ('maximum negative impact') to +3 ('maximum positive impact'). A score of 0 indicates 'no impact'. The final score is the average obtained by adding up the scores for all items and dividing the total by 26.
The F-PIADS will be carried out at the end of the intervention phase. Two assessments will be conducted, one for each device (wheelchair and PPE).
Measured: End of the intervention phase (week 4) : Day 26
Assess the perceived exertion involved in performing four everyday tasks using the Rate of Perceived Exertion (RPE) scale.
The RPE scale is a valid method for quantifying physical exertion across a wide variety of exercise types.
It comprises the following categories: a scale from 0 to 10: 0 None, 1 Very easy, 2 Quite easy, 3 Moderate, 4 Quite difficult, 5 Difficult, 7 Very difficult, 10 Very, very difficult. This scale will be used to assess the perception of exertion after completing each task, whether performed in a wheelchair or using the EVE® exoskeleton.
Measured: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Assessing the reliability of the EVE® exoskeleton.
The performance of the EVE® exoskeleton will be assessed by counting the number of faults that occur during use. A fault is recorded whenever there is an interruption in use that requires the user to return to a seated position, as no other action is then possible.
Measured: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ParaplegiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 5 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape
- Sponsor type
- University, hospital or other
- Collaborators
- Groupement des Hôpitaux de l'Institut Catholique de Lille, Wandercraft
- Responsible party
- Sponsor
- Investigators
- Stéphanie Leplaideur, Physician PhD, Principal investigator, Centre de Kerpape
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07828912
- Sponsor's protocol ID
- 2025-A02452-47
- Acronym
- KER-EXHOME
- Status last verified
- Sep 2026
- First submitted
- 26 Aug 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Personal Exoskeleton or Manual Wheelchair: a Comparison of Performance and Satisfaction in Activities of Daily Living Among People With Spinal Cord Injuries, Using the SCED Methodology.
- ClinicalTrials.gov ID
- NCT07828912
- Acronym / sponsor ID
- KER-EXHOME / 2025-A02452-47
- Conditions
- Paraplegia, Spinal Cord Injury
- Keywords
- manual wheelchair, exoskeleton, personal powered exoskeleton, everyday tasks, satisfaction, performance
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 5 participants (estimated)
- Lead sponsor
- Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KerpapeUniversity, hospital or other
- Collaborators
- Groupement des Hôpitaux de l'Institut Catholique de Lille, Wandercraft
- Study start
- Oct 2026 (estimated)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Spinal cord injuries resulting in paraplegia affect patients' mobility and, consequently, their ability to participate in activities of daily living. In France, according to available sources, the number of people with a symptomatic spinal cord injury is estimated to be between 97,000 and 132,000, with an average age of 55. The incidence is estimated at 1,300 new cases per year.
Following initial treatment, patients' aim is to resume their daily activities. Engaging in these activities is associated with a better quality of life and is recognised as having a positive effect on health. Limitations in their ability to move around directly affect their participation in activities of daily living and, consequently, their quality of life.
To this end, mobility can be supported by a manual wheelchair (MW) or an electric wheelchair (EW); however, these aids do not enable patients to regain the ability to stand, which remains one of the main goals for people with spinal cord injuries.
Robotic exoskeletons can assist with standing and locomotion. To date, robotic exoskeletons have been used in rehabilitation centres. During the rehabilitation phase, these devices have proven to be usable and safe for a wide range of patients with spinal cord injuries. Motorised exoskeletons thus enable patients to perform tasks such as walking, standing upright, rotating, and carrying out dynamic balance exercises.
In the longer term, personal exoskeletons, used at home, could facilitate the performance of productive, domestic, social or recreational activities, such as those carried out on a daily basis by every individual.
Personal powered exoskeletons (PPEs) also appear to generate physiological and psychosocial benefits. Studies describe potential improvements in cardiovascular health, bladder and sphincter function, and a reduced risk of osteoporosis. After a few weeks of training with a motorised exoskeleton, patients report improvements in social functioning, mental health and sub-domains of general health perception on the SF36 Walk Wheel.
It should be noted that the ability to interact socially whilst standing is an important aspect of quality of life for patients with spinal cord injuries. Patients describe the pleasure of eye contact, of being able to walk with assistance, and an improvement in mood. The PPE would complement the wheelchair by enabling ambulation and participation in activities whilst standing.
Preserving upper limb function is a prerequisite for the widespread use of walking exoskeletons in everyday life. A self-supporting PPE, such as the EVE® device, which does not require the use of crutches, aims to enable users to stand up and walk whilst retaining the use of their upper limbs. This active balance control is a crucial function for achieving many functional skills in a domestic environment. One of the technological advantages of the self-balancing exoskeleton lies in the use of dynamics to eliminate the need for crutches, whilst ensuring walking safety.
The next step towards the development of personal exoskeletons for people with spinal cord injuries is to investigate the performance of activities of daily living whilst wearing an exoskeleton. To our knowledge, no such study has been carried out, and our work addresses a gap in the scientific literature by analysing the impact of using a self-propelled PPE on satisfaction and performance when carrying out activities of daily living.
The investigators hypothesise that the personal exoskeleton leads to greater satisfaction when carrying out the four tasks of daily living, compared with that achieved using a manual wheelchair.
In this context, the KER-EXHOME clinical trial, proposed by Dr Stéphanie LEPLAIDEUR (coordinator of this study), and led by the Kerpape Centre (sponsor), aims to compare, in participants with paraplegia, satisfaction and performance when carrying out activities of daily living and physical activities, using the EVE® device compared with a manual wheelchair.
Detailed description
The KER-EXHOME study is a single-case experimental design (SCED) with multiple baseline conditions. This methodology enables the analysis of data from a limited number of subjects and is based on three principles: each subject serves as their own control; frequent, repeated measurement of each subject's performance throughout the study phase; and the sequential, randomised introduction of the intervention during the study, which ensures the necessary statistical power.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Carrying out tasks using the EVE exoskeleton and a manual wheelchair. | Experimental | Device: Carrying out tasks using the EVE exoskeleton and a manual wheelchair.Training Phase, Week 1 The training phase for operating the EVE® exoskeleton covers the following functions (designed to ensure that the participant is trained in the use of the EVE® exoskeleton): * Standing up; * Testing in free mode; * Walking; * Turning round; * Half-squat; * Using precision mode; * Sitting down; * Carrying out emergency extraction training; * Archery training, if the participant has no prior experience. Participants will undergo training over 5 sessions, each lasting at least 60 minutes, spread over one week. A minimum of 5 hours' training is required to ensure safety. Intervention phase, weeks 2 to 4 During this phase, participants will have a 3½-hour session every day (Monday to Friday). During each session, tasks will need to be carried out using the EVE® exoskeleton and the manual wheelchair. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Clinical presentation of paraplegia at a level between T5 and L5 inclusive, AIS A to C inclusive
- Secondary to a spinal cord injury (traumatic or non-traumatic) occurring more than 6 months ago, clinically and functionally stable
- Using a manual wheelchair for indoor and outdoor mobility
- Able to tolerate 45 minutes of standing per day
- Anthropometric compatibility with the device (weight, height, lower limb measurements, joint ranges of motion);
Key exclusion criteria (24 listed)
- Osteoporosis with a T-score < -2.5 at the femoral neck, as shown by a bone densitometry scan carried out within the last 12 months.
- History of osteoporotic fracture(s)
- Condition or treatment causing secondary osteoporosis (known thyroid disorder, known hypogonadism, known chronic gastrointestinal disease (ulcerative colitis and Crohn's disease), corticosteroid therapy, use of bisphosphonates for more than three months, early menopause (before the age of 45), abnormal calcium metabolism test results)
- Progressive intercurrent conditions: pressure ulcers, infection, venous thrombosis
- Cardiovascular or pulmonary conditions contraindicating exercise (e.g. heart failure or coronary artery disease within the last 6 months)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Carrying out tasks using the EVE exoskeleton and a manual wheelchair.Each day (Monday to Friday), participants will have a 3½-hour session. During each session, tasks will need to be carried out using the EVE® exoskeleton and the manual wheelchair. The tasks have been grouped in pairs so that two tasks are carried out in succession. These task groups have been assigned a number, as follows: 1- Archery and retrieving a parcel 2- Making coffee and brushing teeth During a session, the participant will carry out one task group using both devices: the EVE® exoskeleton and the manual wheelchair. These devices have been assigned a letter, as follows: A- EVE® exoskeleton B- Manual wheelchair A random allocation will be used to determine the order of the parameters (B-wheelchair or A-EVE® exoskeleton), the time of day (morning or afternoon), and the task group to be performed in each session for each participant (1 or 2). | Device | Carrying out tasks using the EVE exoskeleton and a manual wheelchair. |
Primary outcome
Compare satisfaction and performance when carrying out four activities of daily living using the EVE® exoskeleton, versus those carried out using a manual wheelchair, using the Canadian Occupational Performance Measure (COPM)
Time frame: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
The Canadian Occupational Performance Measure (COPM) will be used to compare perceived satisfaction and performance when carrying out identified activities of daily living using either the EVE® exoskeleton or a manual wheelchair. Using the COPM, satisfaction and performance are assessed on a scale of 1 to 10 (1 = very poor performance and satisfaction, 10 = full performance and satisfaction). MCRO scores show a significant improvement between the start and end of treatment; in the SCI validation study, the average improvement reported is approximately 4.25 points (Performance) and 2.96 points (Satisfaction) between two measurement points. The MCRO will be carried out at the end of each session using one of the devices (wheelchair or exoskeleton). Two assessments must be carried out per half-day.
6 secondary outcomes
Compare user-assessed performance with clinician-assessed performance, using the Performance Quality Rating Scale (PQRS)
Time frame: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Time taken to complete each task (in seconds).
Time frame: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
To evaluate the user's perception of the ease of use of the EVE® exoskeleton, using the System Usability Scale (SUS)
Time frame: Intervention phase (Week 2 to 4) : Day 12, Day 19, Day 26
To assess the psychosocial impact of the EVE® exoskeleton using the French-Canadian version of the F-PIADS scale, which measures the psychosocial impact of an assistive device.
Time frame: End of the intervention phase (week 4) : Day 26
Assess the perceived exertion involved in performing four everyday tasks using the Rate of Perceived Exertion (RPE) scale.
Time frame: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Assessing the reliability of the EVE® exoskeleton.
Time frame: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Paraplegia
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Recruiting
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Spinal Cord Injury, Acute
Active, not recruiting
Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic Paraplegia
Hereditary Spastic Paraplegia
Recruiting
Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury
Fecal Incontinence
RecruitingPhase 2/3
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Spinal Cord Injury, Traumatic Spinal Cord Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marie-Caroline Delebecque, project manager contact
Stéphanie Leplaideur, Physician PhD principal investigator
Centre de Kerpape
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Carrying out tasks using the EVE exoskeleton and a manual wheelchair. in people with Paraplegia and Spinal Cord Injury, run by Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charline Longuet, clinical research assistant (0297826293 ext. +33, charline.longuet@vyv3.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare satisfaction and performance when carrying out four activities of daily living using the EVE® exoskeleton, versus those carried out using a manual wheelchair, using the Canadian Occupational Performance Measure (COPM) (time frame: Intervention phase (Week 2 to 4) : Day 8, Day 9, Day 10, Day 11, Day 12, Day 15, Day 16, Day 17, Day 18, Day 19, Day 22, Day 23, Day 24, Day 25). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.